GPVI

Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke

Retrieved on: 
Monday, December 5, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Stroke, Document, Standard of care, CHMP, Intracerebral hemorrhage, Medicine, MAA, Mab, Agency, Centre de documentation de la musique contemporaine, EMA, Patient, Disability, Death, Infarction, ESOC, Regulatory affairs, ISIN, Biotechnology, Rankine scale, Committee, Particle-size distribution, GPVI, European Medicines Agency, Medication, AIS, PRIME, Clinical trial, Safety, A&B, Brain, Mortality, Marketing, VI, Thrombectomy, Committee for Medicinal Products for Human Use, Pharmaceutical industry, Medical imaging, INSERM

The discussion meeting took place remotely in October 2022, and Acticor Biotech provided a list of questions concerning the non-clinical development and the study design of the ACTISAVE study.

Key Points: 
  • The discussion meeting took place remotely in October 2022, and Acticor Biotech provided a list of questions concerning the non-clinical development and the study design of the ACTISAVE study.
  • Although CHMP recommendations were issued to further detail some analyses, the statistical methodology was therefore endorsed on its general principles.
  • In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Acticor Biotech or not currently considered material by Acticor Biotech.

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

Retrieved on: 
Tuesday, November 22, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Clinical trial, CTU, Brain, Survival, University, Centre de documentation de la musique contemporaine, European Medicines Agency, Infarction, STEMI, University Hospitals Birmingham NHS Foundation Trust, Stroke, A&B, BHP, Blood, Medicine, ISIN, Queen Elizabeth Hospital, Degenerative disease, Partnership, Myocardial infarction, ESOC, Mortality, Intracerebral hemorrhage, Clinical trials unit, MI, University of Birmingham, EMA, Document, Angioplasty, Queen Elizabeth Hospital Birmingham (1933–2010), Thrombosis, GPVI, Therapy, Mab, Hospital, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Northern General Hospital, VI, Associate, Heart, Patient, Medical device, Pharmaceutical industry, INSERM, Cardiology

Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

Key Points: 
  • Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.
  • A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK.
  • Although immediate opening of the blocked coronary artery by angioplasty in cases of heart attack is now routine, significant heart damage still occurs.
  • Were delighted to work with Acticor to see whether this new class of drug has the potential to improve the outcomes of our patients with heart attacks.

Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke

Retrieved on: 
Monday, September 26, 2022
Research, FDA, Neurology, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Newton, Safety, Microcirculation, Cuban Neuroscience Center, Patient, Clinical trial, Stroke, Research, Disease, National Institute, Intracranial hemorrhage, ISIN, Food, European Medicines Agency, GPVI, A&B, Breakthrough therapy, VI, Thrombectomy, Intracerebral hemorrhage, Mortality, EMA, FDA, Phase, ESOC, Incidence, Infarction, Brain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Standard of care, Mab, Medicine, Pharmaceutical industry, MD, INSERM

Chattanooga CHI Memorial is a state-of-the-art stroke unit that receives 1,400 stroke patients per year in unprecedented medical conditions, with a large part given to research. "

Key Points: 
  • Chattanooga CHI Memorial is a state-of-the-art stroke unit that receives 1,400 stroke patients per year in unprecedented medical conditions, with a large part given to research. "
  • ACTICOR had obtained an IND1 for this study from the U.S. Food and Drug Administration (FDA) in November 2021 and had initiated enrollment in Europe in the third quarter of 2021.
  • The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients.
  • In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke.

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Retrieved on: 
Thursday, July 21, 2022
Health, FDA, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Newton, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intracerebral hemorrhage, VI, Brain, Mab, Mortality, Medicine, Food, A&B, ISIN, National Institute, EMA, CMO, Safety, GPVI, Thrombectomy, Stroke, ESOC, Clinical trial, European Medicines Agency, FDA, Standard of care, Patient, Infarction, General manager, IND, Pharmaceutical industry, INSERM

ACTICOR BIOTECH (Paris:ALACT) (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.

Key Points: 
  • ACTICOR BIOTECH (Paris:ALACT) (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.
  • The "PRIME" status granted by the European Medicines Agency (EMA) allows to reinforce the support for the development of drugs that target an unmet medical need.
  • This status will allow Acticor Biotech to strengthen interactions and obtain early dialogues with regulatory authorities in order to confirm the clinical development plan for glenzocimab in the treatment of stroke.
  • Yannick Pletan, General Manager & CMO of Acticor Biotech, said: "We are delighted that the European Medicines Agency has granted "PRIME" status to glenzocimab.

ACTICOR BIOTECH: Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022

Retrieved on: 
Monday, May 9, 2022
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Newton, GPVI, Brain, Stroke, VI, Physician, NGO, A&B, IS, ESO, ISIN, Human, Mab, National Institute, Medicine, Pharmaceutical industry, INSERM

The positive results of the ACTIMIS phase 1b/2a study were presented on February 22, 2022 ( link to the press release ).

Key Points: 
  • The positive results of the ACTIMIS phase 1b/2a study were presented on February 22, 2022 ( link to the press release ).
  • The European Stroke Organisation (ESO) is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007.
  • The aim of the ESO is to reduce the burden of stroke by changing the way that stroke is viewed and treated.
  • The 8th conference of the European Stroke Organisation took place on May 4, 5 and 6, 2002 in Lyon.

Acticor Biotech Announces Its 2021 Full-year Financial Results and Gives an Update on Its Clinical Development

Retrieved on: 
Wednesday, March 30, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Newton, Mission statement, Medicine, A&B, Diabetes, Myocardial infarction, Mab, ISIN, COVID-19, AP-HP, GREEN, Thrombectomy, Population, Risk, Investigational New Drug, Biotechnology, Director, Brain, Centre de documentation de la musique contemporaine, IPO, Pulmonary embolism, IFRS, GPVI, Assistance, Clinical trial, Mortality, Board, Financial Market Authority (Liechtenstein), National Institute, Euronext Growth, VI, Review, Document, AIS, FDA, Acute respiratory distress syndrome, Patient, Company, Stroke, IND, Individual, Research, Food, Safety, Statutory auditor, US Foods, Pharmaceutical industry, Security (finance), Holding company, Audit, INSERM

We recently obtained very promising results for our ACTIMIS phase 1b/2a clinical trial in this indication, and which confirm the clinical interest of GPVI inhibition.

Key Points: 
  • We recently obtained very promising results for our ACTIMIS phase 1b/2a clinical trial in this indication, and which confirm the clinical interest of GPVI inhibition.
  • Research and development costs1 amounted to 7,766 thousand in 2021 compared with 5,770 thousand in 2020.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Acticor Biotech or not currently considered material by Acticor Biotech.
  • The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Acticor Biotech to be materially different from such forward-looking statements.

Spleen Tyrosine Kinase (SYK) Inhibitors Drug Pipeline Market Report 2022 with Insights from Genosco, Portola Pharma, GSK, FUJIFILM, TopiVert, Takeda Oncology, & Asana BioSciences - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 9, 2022
Pharmaceutical, Health, Clinical Trials, News, SYK, Organic acid, Mammal, Antigen presentation, Cell, Macrophage, NK, II, SRC, Rheumatoid arthritis, Clinical trial, B cell, Fc receptor, Invertebrate, Inhibitor, Allergy, BCR, GPVI, Therapy, ZAP70, SH2, Degenerative disease, Neutrophil, Discovery, Pharmaceutical industry, Vaccine, Non-receptor tyrosine kinase

The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Spleen Tyrosine Kinase (SYK) Inhibitors- Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
  • SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells.
  • The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities.

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Retrieved on: 
Thursday, November 4, 2021
Biotechnology, FDA, Pharmaceutical, Health, Newton, Safety, Texas Medical Center, A&B, Achievement, Memorial Hermann–Texas Medical Center, Industry, Clinical trial, Chapter Three, Euronext Growth, Severe acute respiratory syndrome coronavirus 2, Disease, GPVI, Growth, COVID-19, Stroke, Standard of care, Forward-looking statement, National Institute, Thrombectomy, Children's Memorial Hermann Hospital, ISIN, Biotechnology, Environment, IPO, Medicine, Rankine scale, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRS, Silchester International Investors, Patient, Bleeding, FDA, VI, IND, Pharmaceutical industry, glenzocimab (ACT017), the Therapeutic Candidate, glenzocimab and COVID-19, ACTICOR BIOTECH, GLENZOCIMAB (ACT017), THE THERAPEUTIC CANDIDATE, GLENZOCIMAB AND COVID-19, ACTICOR BIOTECH

This active IND represents a significant milestone and marks the launch in the US of the Phase 2/3 clinical trial with glenzocimab in acute ischemic stroke as an add-on therapy to standard of care for this indication.

Key Points: 
  • This active IND represents a significant milestone and marks the launch in the US of the Phase 2/3 clinical trial with glenzocimab in acute ischemic stroke as an add-on therapy to standard of care for this indication.
  • The development of new therapeutic options for the treatment of the acute phase of ischemic stroke without increasing the bleeding risk, is a major medical need of the coming years.
  • The FDA acceptance of an IND application for glenzocimab and the clinical program that will be conducted by Acticor Biotech in the US constitute important steps to offer new safe treatments to stroke patients, says Pr.
  • Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab).

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Retrieved on: 
Saturday, October 30, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Newton, Safety, CMS, Neurology, GPVI, Research, Hoffmann-La Roche, Innovation, VI, Medicine, Patient, Texas, Mediolanum, Stroke, Memorial Hermann–Texas Medical Center, Chief executive officer, Paris, Paris-Sud University, Nature, Texas Medical Center, International, Company, Mobile stroke unit, CEO, Growth, National Institute, Children's Memorial Hermann Hospital, Biotechnology, Pharmaceutical industry, glenzocimab (ACT017), the Therapeutic Candidate, glenzocimab and Stroke, Acticor Biotech, GLENZOCIMAB (ACT017), THE THERAPEUTIC CANDIDATE, GLENZOCIMAB AND STROKE, ACTICOR BIOTECH

Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.

Key Points: 
  • Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.
  • This collaboration aims to prepare an international clinical trial ACTISAVE to evaluate the efficacy of glenzocimab in patients suffering from acute ischemic stroke.
  • This eighth edition of the Galien Medstartup Awards was chaired by Bernard Poussot, Director of Roche Holding and former Chairman & CEO of Wyeth.
  • This year again, the event featured a remarkable world-renowned panel, rewarding the most innovative projects in the healthcare industry.